Product Center
-
Ab&B Bio and Yither Bio have both obtained qualification certification!
2024-12-30Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) have been recognized as Jiangsu Province's specialized and innovative small and medium-sized enterprises and national high-tech enterprises, respectively.
Read More -
The kickoff meeting for clinical research on the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome was successfully held
2024-12-25Recently, the clinical launch meeting for the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome, in collaboration with Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） was successfully held at the research site in Guangdong. This clinical study is sponsored and conducted by Guangzhou Women and Children's Medical Center as the core research unit, aiming to provide evidence-based influenza vaccination for children with nephrotic syndrome as a special group, in order to reduce their risk of influenza virus infection and severe infection.
Read More -
Influenza virus subunit vaccine (adjuvant) IND application approved
2024-10-30Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) jointly applied for a Class I new drug "Influenza Virus Subunit Vaccine (Adjuvant)" IND application, which has been approved by the Drug Evaluation Center (CDE) of the China National Medical Products Administration. The approval of this vaccine marks the completion of the full coverage of the company's subunit influenza vaccine product pipeline for trivalent and quadrivalent influenza virus subunit vaccines, providing the most accurate selection for different age groups and different demand groups.
Read More -
The application for the marketing of trivalent influenza virus subunit vaccine has been accepted!
2024-10-08Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）has received acceptance from the Drug Evaluation Center (CDE) of the China National Medical Products Administration for its application to market the "6-35 month old trivalent influenza virus subunit vaccine" and the "3-year-old and above trivalent influenza virus subunit vaccine". This acceptance marks the final sprint stage of the first domestic full dose trivalent influenza virus subunit vaccine for people aged 6 months and above, which is about to be launched!
Read More
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
